Reyvow

Reyvow is the brand name for lasmiditan, a prescription medication approved for the acute treatment of migraine in adults. It belongs to the ditan class of drugs and acts as a selective agonist of the 5-HT1F receptor. Unlike triptans, lasmiditan does not cause cerebral vasoconstriction, and its development aimed to provide an option for patients who may be intolerant or contraindicated to vasoconstrictive migraine therapies.

Indication and administration: Reyvow is indicated for the acute treatment of migraine with or without aura in adults. It is taken as an oral tablet at the onset of a migraine attack. The available tablet strengths are 50 mg, 100 mg, and 200 mg. A single dose should be taken per attack, and no more than 200 mg should be taken in a 24-hour period. A second dose is not recommended within 24 hours.

Safety and adverse effects: Common adverse effects include dizziness, fatigue, somnolence, paresthesias, and nausea. Because of potential central nervous system effects, patients should avoid driving or operating heavy machinery for at least 8 hours after dosing. Caution is advised with alcohol or other CNS depressants. Safety in certain populations, such as those with liver impairment, requires medical consultation, and dose adjustments or contraindications may apply.

Regulatory status and development: Reyvow was developed by Eli Lilly and approved by the U.S. Food and Drug Administration in 2019 for adults with acute migraine. It provides an alternative for patients who may not respond to or tolerate vasoconstrictive migraine medications, and it represents the first-in-class 5-HT1F receptor agonist.